Comparable efficacy of low- versus high-dose induction corticosteroid treatment in autoimmune pancreatitis

Pancreas

Volumn 43, Issue 2, 2014, Pages 261-267

  Buijs, Jorie ^a   Van Heerde, Marianne J ^a   Rauws, Erik A J ^b   De Buy Wenniger, Lucas J Maillette ^b   Hansen, Bettina E ^a   Biermann, Katharina ^a   Verheij, Joanne ^b   Vleggaar, Frank P ^c   Brink, Menno A ^d   Beuers, Ulrich H W ^b   Kuipers, Ernst J ^a   Bruno, Marco J ^a   Van Buuren, Henk R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

autoimmune pancreatitis; IgG4; steroid therapy

Indexed keywords

ADULT; AGED; AUTOIMMUNE DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INDUCTION CHEMOTHERAPY; JAUNDICE; MALE; MIDDLE AGED; PANCREATITIS; PREDNISONE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84894452095     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000044     Document Type: Article

References (26)

1. Okazaki K, Chiba T. Autoimmune related pancreatitis. Gut. 2002;51:1-4.
2. Detlefsen S, Mohr Drewes A, Vyberg M, et al. Diagnosis of autoimmune pancreatitis by core needle biopsy: application of six microscopic criteria. Virchows Arch. 2009;454:531-539.
3. Erkelens GW, Vleggaar FP, Lesterhuis W, et al. Sclerosing pancreato-cholangitis responsive to steroid therapy. Lancet. 1999;354:4344.
4. Nishino T, Toki F, Oyama H, et al. Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy. Intern Med. 2006;45:497-501.
5. Kamisawa T, Yoshiike M, Egawa N, et al. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study. Pancreatology. 2005;5:234-238; discussion 238-240.
6. Kamisawa T, Egawa N, Inokuma S, et al. Pancreatic endocrine and exocrine function and salivary gland function in autoimmune pancreatitis before and after steroid therapy. Pancreas. 2003;27:235-238.
7. Chari ST, Smyrk TC, Levy MJ, et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol. 2006;4:1010-1016; quiz 1934.
8. Kamisawa T, Okazaki K, Kawa S, et al. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol. 2010;45:471-477.
9. Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58:1504-1507.
10. Sandanayake NS, Church NI, Chapman MH, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/ immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2009;7:1089-1096.
11. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96:23-43.
12. Panthakalam S, Bhatnagar D, Klimiuk P. The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J. 2004;49:139-141.
13. Uzu T, Harada T, Sakaguchi M, et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract. 2007;105:c54-c57.
14. Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154:97-101.
15. Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40:352-358.
16. Otsuki M, Chung JB, Okazaki K, et al. Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan-Korea Symposium on Autoimmune Pancreatitis. J Gastroenterol. 2008;43:403-408.
17. Hirano K, Tada M, Isayama H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut. 2007;56:1719-1724.
18. Kamisawa T, Okamoto A, Wakabayashi T, et al. Appropriate steroid therapy for autoimmune pancreatitis based on long-term outcome. Scand J Gastroenterol. 2008;43:609-613.
19. Ito T, Nishimori I, Inoue N, et al. Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan. J Gastroenterol. 2007;42(suppl 18):50-58.
20. Watanabe M, Yamaguchi K, Kobayashi K, et al. Autoimmune pancreatitis diagnosed after pancreatoduodenectomy and successfully treated with low-dose steroid. J Hepatobiliary Pancreat Surg. 2007;14:397-400.
21. Nishimori I, Tamakoshi A, Kawa S, et al. Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis: findings from a nationwide survey in Japan. Pancreas. 2006;32:244-248.
22. Uchida K, Yazumi S, Nishio A, et al. Long-term outcome of autoimmune pancreatitis. J Gastroenterol. 2009;44:726-732.
23. Kauh E, Mixson L, Malice MP, et al. Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals. Eur J Endocrinol. 2012;166:459-467.
24. Kamisawa T, Kim MH, Liao WC, et al. Clinical characteristics of 327 Asian patients with autoimmune pancreatitis based on Asian diagnostic criteria. Pancreas. 2011;40:200-205.
25. Boumpas DT, Chrousos GP, Wilder RL, et al. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med. 1993;119:1198-1208.
26. Moon SH, Kim MH, Park DH, et al. Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study. Gut. 2008;57:1704-1712.